Navigation Links
Pergamum to Provide Effective Development of Innovative Dermatology and Wound Healing Companies
Date:9/10/2009

STOCKHOLM, September 10 /PRNewswire/ -- Pergamum AB has announced its formation; Pergamum will commercialize the Karolinska Development dermatology and wound healing interests, and create a broad-based therapeutic company in its focus areas.

The Pergamum product pipeline consists of five development projects, three of which are undergoing clinical trials. Indications covered within the portfolio include improved wound healing and reduced scar formation, healing hard-to-heal-wounds, the prevention of bacterial and fungal infections, atopic dermatitis and infected wounds and burns.

Pergamum CEO Magnus Precht will present Pergamum at the Rodman & Renshaw Annual Global Investment Conference in New York September 9-11, 2009 and will be available for one-on-one meetings with investors and potential partners during the conference.

"Pergamum represents a unique approach to developing new biopharmaceuticals in the dermatology and wound care markets," said Magnus Precht, CEO of Pergamum AB. "The fact that the group is working within related fields means we are able to build capabilities and specialist knowledge tailored to the needs of the group. We will provide individual projects with access to technical skills and key competencies without creating bureaucratic layers. This should translate into improved quality, cost savings and, ultimately, a shorter path to regulatory approval. It also means we have a broader, more attractive offering when meeting with pharma companies to discuss eventual sales or licensing opportunities," added Mr Precht.

Pergamum's current projects include: wound healing (Omnio Healer), atopic dermatitis / anti-inflamatory (BioCis Pharma), atopic dermatitis / anti-infective (DermaGen), anti-adhesion / wound healing (PharmaSurgics), and wound healing for chronic wounds (Lipopeptide). Karolinska Development owns 64% of Pergamum, with the other owners being Ostersjostiftelsen (The Foundation for Baltic and East European Studies) and Midroc New Technology.

Karolinska Development's CEO, Conny Bogentoft, said, "We are extremely pleased with this new initiative. By consolidating all of our interests in the dermatology and wound healing field in this way we have created an extremely resource-efficient business model. It should provide both more effective project development and greater efficiency when seeking exit opportunities."

About Karolinska Development:

Managing one of the largest portfolios of life science research companies in Europe, Karolinska Development

AB is a new type of company focused on filling the innovation gap within the pharmaceutical industry. Using a unique, highly cost-effective model Karolinska Development commercializes internationally renowned life science innovations, helping to deliver the medical products of the future.

    For more information please contact:

    Magnus Precht, CEO, Pergamum AB
    European mobile phone: +46-73-515-7450
    US cell phone:         +1-817-312-7277
    magnus.precht@pergamum.com
   http://www.pergamum.com

    Conny Bogentoft, CEO, Karolinska Development AB
    Cell phone: +46-70-668-61-43
    info@karolinskadevelopment.com
   http://www.karolinskadevelopment.com


'/>"/>
SOURCE Karolinska Development AB
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
2. Hyland Software Provides Grant Assistance to Kick-Start Technology Projects
3. PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million
4. ValGenesis, Inc., the Leading Provider of Validation Lifecycle Management Solutions to Regulated Life Science Companies, Today Announced Support for EMC Documentum v.6.5
5. ChemBridge Corporation and Collaborative Drug Discovery Announce Strategic Collaboration to Provide Diverse Chemical Libraries Together With Researchers Own Private Data
6. Ambry Genetics Announces Certified Service Provider Status for Agilent Microarrays
7. Leading European Contract Research Organization Selects OmniComm to Provide eClinical Solutions for Important Phase III Study
8. Wyeth Provides Regulatory Update on Prevnar 13* in the United States
9. Sigma-Aldrich Acquires ChemNavigator, Inc., to Provide Researchers With Industry-Leading Chemical Compound Selection and Procurement Services
10. ThermoGenesis Provides Update on Fiscal 2009 Results
11. GeoVax Labs, Inc. Provides Clinical Studies Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 5, 2016  In the pharmaceutical industry the medical ... of launch activities including the identification and engagement of ... is especially high in the oncology therapeutic area where ... and the Role of Medical Affairs in Oncology Launch ... oncology therapies find better ways to utilize medical affairs ...
(Date:2/5/2016)... , February 5, 2016 Amarantus ... biotechnology company focused on developing products for Regenerative Medicine, ... Rare Pediatric Disease Designation (RPDD) from the US Food ... with MANF. MANF was previously granted orphan drug designation ... --> Amarantus BioScience Holdings, Inc. (OTCQB: ...
(Date:2/4/2016)... San Francisco, CA (PRWEB) , ... February 04, ... ... future of enterprise talent development and compliance training, today announced an interactive ... on Morf Playbook™. The RAPS (Regulatory Affairs Professional Society) accredited interactive course ...
(Date:2/4/2016)... , Feb. 4, 2016  Sangamo BioSciences, Inc. ... editing, announced today that Edward Lanphier , Sangamo,s ... on the progress of Sangamo,s ZFP Therapeutic ® ... strategy at 2:40 pm ET on Thursday, February 11, ... Global Healthcare Conference. The conference is being held in ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
(Date:2/2/2016)... Feb. 2, 2016   Parabon NanoLabs ... U.S. Army Research Office and the Defense Forensics ... sensitivity of the company,s Snapshot Kinship Inference ... and, more generally, defense-related DNA forensics.  Although Snapshot ... (predicting appearance and ancestry from DNA evidence), it ...
(Date:2/1/2016)... , February 1, 2016 Rising ... to drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new ... market size through 2020   ... coupled with new technological advancements to drive global touchfree ...
Breaking Biology News(10 mins):